Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Haleon (HLN.L)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date	Stock Price (p)	Price Target (p)	Rating
2021-09-02	NaN	-	No Rating
2022-07-19	301	380	Buy
2022-10-14	274	410	Buy
2023-01-13	325	400	Buy
2023-04-21	352	410	Buy
2023-10-10	340	430	Buy
2023-11-02	320	420	Buy
2024-01-15	334	410	Buy
2024-10-07	377	445	Buy

Disclosures

UBS has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
UBS is acting as FA to Haleon on the acquisition of an additional stake in Tianjin TSKF Pharmaceutical Co Ltd.
Within the past 12 months, UBS has received compensation for investment banking services from this company/entity or one of its affiliates.
UBS expects to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
UBS AG London Branch acts as broker to this company.
UBS Securities LLC makes a market in the securities and/or ADRs of this company.
UBS holds a long or short position of 0.5% or more of the listed shares of this company.

Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.